AU2005294258A1 - Method for the treatment of polycystic kidney disease - Google Patents

Method for the treatment of polycystic kidney disease Download PDF

Info

Publication number
AU2005294258A1
AU2005294258A1 AU2005294258A AU2005294258A AU2005294258A1 AU 2005294258 A1 AU2005294258 A1 AU 2005294258A1 AU 2005294258 A AU2005294258 A AU 2005294258A AU 2005294258 A AU2005294258 A AU 2005294258A AU 2005294258 A1 AU2005294258 A1 AU 2005294258A1
Authority
AU
Australia
Prior art keywords
carbon atoms
alkyl
inhibitor
phenyl
carbon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005294258A
Other languages
English (en)
Inventor
Philip Frost
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of AU2005294258A1 publication Critical patent/AU2005294258A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2005294258A 2004-10-08 2005-10-07 Method for the treatment of polycystic kidney disease Abandoned AU2005294258A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61698104P 2004-10-08 2004-10-08
US60/616,981 2004-10-08
PCT/US2005/036122 WO2006042100A2 (en) 2004-10-08 2005-10-07 Method for the treatment of polycystic kidney disease

Publications (1)

Publication Number Publication Date
AU2005294258A1 true AU2005294258A1 (en) 2006-04-20

Family

ID=36013658

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005294258A Abandoned AU2005294258A1 (en) 2004-10-08 2005-10-07 Method for the treatment of polycystic kidney disease

Country Status (12)

Country Link
US (1) US20060079515A1 (https=)
EP (1) EP1796727A2 (https=)
JP (1) JP2008515913A (https=)
CN (1) CN101102757A (https=)
AR (1) AR052221A1 (https=)
AU (1) AU2005294258A1 (https=)
BR (1) BRPI0516533A (https=)
CA (1) CA2580864A1 (https=)
MX (1) MX2007004001A (https=)
PE (1) PE20060681A1 (https=)
TW (1) TW200616612A (https=)
WO (1) WO2006042100A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
EP1942937A1 (en) 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
EP2142498A2 (en) 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
US20100099677A1 (en) * 2008-04-21 2010-04-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Thiazole Derivatives
WO2009131957A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
BRPI0914790A2 (pt) 2008-06-17 2015-10-20 Wyeth Llc uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
JP2012503005A (ja) * 2008-09-19 2012-02-02 インスティテュート フォア ワンワールド ヘルス イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
FR2947268B1 (fr) * 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
JP5931876B2 (ja) 2010-08-26 2016-06-08 シンフォニー エボリューション， インコーポレイテッド 多発性嚢胞腎を処置するためのレセプタータイプキナーゼの調節因子の使用
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
MX368903B (es) 2013-02-20 2019-10-21 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9458169B2 (en) 2013-11-01 2016-10-04 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
CA2357110A1 (en) * 2001-04-11 2002-10-11 American Cyanamid Company Method for the treatment of polycystic kidney disease
AR037438A1 (es) * 2001-11-27 2004-11-10 Wyeth Corp 3-cianoquinolinas como inhibidores de egf-r y her2 quinasas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos

Also Published As

Publication number Publication date
AR052221A1 (es) 2007-03-07
US20060079515A1 (en) 2006-04-13
CN101102757A (zh) 2008-01-09
EP1796727A2 (en) 2007-06-20
PE20060681A1 (es) 2006-08-28
WO2006042100A2 (en) 2006-04-20
BRPI0516533A (pt) 2008-09-09
MX2007004001A (es) 2007-05-11
TW200616612A (en) 2006-06-01
WO2006042100A3 (en) 2007-06-07
JP2008515913A (ja) 2008-05-15
CA2580864A1 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
AU2005294258A1 (en) Method for the treatment of polycystic kidney disease
JP6162687B2 (ja) 新規のビスアミノキノリン化合物、それから調製した医薬組成物、及びそれらの使用
RU2309150C2 (ru) 3-цианохинолины в качестве ингибиторов egf-r и her2 киназ
EP1379507B1 (en) HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS
KR20020018201A (ko) 결장 폴립 및 결장직장암의 치료 또는 억제용엔에스에이아이디 및 이지에프알 키나제 억제제 함유 조성물
KR102011641B1 (ko) 치환된 퀴나졸리논을 위한 경구 즉시 방출 제형
MXPA02008836A (es) Uso de cianoquinolinas para tratar o inhibir los polipos colonicos.
CN108366992A (zh) 蛋白水解靶向嵌合体化合物及其制备和应用方法
JP2002519379A (ja) 関節症を治療するためのファルネシルタンパク質トランスフェラーゼ阻害剤
CA1330660C (en) Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders
CA2122841A1 (en) Quinolone derivatives
CN105777464A (zh) 异羟肟酸衍生物及其制备方法和应用
JP4377454B2 (ja) Ｎｋ３拮抗物質としてのキノリン誘導体の塩
JP2575569B2 (ja) 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法
EP1488808B1 (en) Remedies for glomerular diseases
KR19990067528A (ko) 카인산 신경 세포 독성 억제제 및 피리도티아진 유도체
RU2294198C2 (ru) Производные арил(или гетероарил)азолилкарбинола для лечения респираторных заболеваний
US5476858A (en) Use of carbostyril to increase somatostatin or for inhibiting decrease of somatostatin to treat diseases related thereto
RU95109440A (ru) Производные 4-хинолинила, обладающие антигеликобактериальной активностью, способ их получения, фармацевтическая композиция, их содержащая, и способ ее получения
AU2004222642A1 (en) Phenylcarboxyl acid amides and IK channel inhibitors combination and the use thereof for treating atrial arrhythmia
CZ378597A3 (cs) Použití derivátů pyrrolidinu k léčení alkoholismu
JP7495758B2 (ja) マクロライド化合物及びその慢性呼吸器疾患の治療用途
HK40102216A (zh) 取代的三环酰胺及其类似物的合成
TW202617705A (zh) 作為cyp11a1抑制劑之雜環化合物
HK1190718A (en) Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application